This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

I Was Wrong About Ariad Pharma and Here's Why

CAMBRIDGE, Mass. ( TheStreet) -- I missed the call on Ariad Pharmaceuticals (ARIA - Get Report). While it's true that no one is right with all their stock picks, it's little comfort because I greatly dislike being wrong and losing money. The only positive that can come out of missing Iclusig's toxicity and getting Ariad wrong is learning from the mistake and trying not to repeat it in the future.

What did I miss with Ariad?

I fell prey to confirmation bias. In general, when you're long a stock, you're more likely to dismiss neutral and negative news and/or spin it positively. The opposite is true when you're shorting a stock. In other words, once you make a decision to buy or short a stock, you tend to see all additional information as confirming your position.

Obviously, investors should try to minimize confirmation bias but one can never completely escape its effects. This is why I like engaging the bear thesis when I'm long. It forces you to rethink or re-evaluate your investment thesis.

There were certainly bits of information about Iclusig's safety profile that in retrospect were more serious than I originally believed. The changes made to the protocol of the phase III front-line EPIC study -- excluding more patients with pre-existing cardiovascular conditions -- was probably the most important signal I overlooked.

I interpreted the changes made to the EPIC study as Ariad trying to get a cleaner test of the "dirty drug" hypothesis. I also felt the changes were not out of line relative to changes made to studies involving similar CML drugs.

Interpreting these changes to the most important Iclusig clinical trial as relatively benign was a mistake. More skepticism was clearly needed.

The lower dose of Iclusig introduced into the "Cortes" study at MD Anderson could have confirmed the elevated safety risk, but again, I saw nothing wrong because competing CML drugs are also often dosed lower than their labels prescribe. The changes made to the "Cortes" study should have given me more pause.

What really threw me, however, was the lack of adverse events reported in the FDA's adverse event database. I assumed if Iclusig's safety risk was really significant, it would have showed up in the FDA database, but it wasn't (yet.) Instead, Iclusig-related adverse events showed up in the long-term followup from patients enrolled in the pivotal PACE study used to get the drug approved. I was looking in the wrong place for clues to Iclusig's safety.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARIA $6.36 -0.70%
TSLA $235.00 1.50%
YHOO $33.71 2.30%
AAPL $118.40 0.08%
FB $105.07 0.80%


Chart of I:DJI
DOW 17,847.30 +127.38 0.72%
S&P 500 2,087.31 +6.90 0.33%
NASDAQ 5,130.6610 +21.9950 0.43%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs